RICHLAND, Wash., Sept. 25, 2017 /PRNewswire/ -- IsoRay, Inc.
(NYSE MKT: ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced a poster presentation at the 2017 Annual
American Society for Radiation Oncology (ASTRO) Conference, the
premier radiation oncology society in the world, being held on
September 24-27, 2017. The poster,
entitled "Long-term PSA Outcomes in a Single Institution,
Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate
Brachytherapy Trial", was presented by Dr. Brian Moran, Medical Director, Prostate Cancer
Foundation of Chicago,
Westmont, Illinois.
The trial's objective was to evaluate biochemical outcomes of a
randomized group of low to intermediate risk, localized prostate
cancer patients treated with permanent iodine-125 (I-125) or
cesium-131 (Cs-131) brachytherapy. Median follow-up was 95 months
for the 140-patient group. At nine years, the biochemical
relapse-free survival (BRFS) was statistically equivalent for both
groups, 89% for the I-125 group and 86% for the Cs-131 group
(p=0.45). BRFS refers to a sensitive means of detecting
persistent prostate cancer by measuring and trending prostate
specific antigen (PSA) levels in the blood over time.
"The results of this trial, the longest data set available to
date, demonstrates that permanent, low dose rate brachytherapy with
Cesium-131 provides excellent PSA-based outcomes for low to
intermediate risk localized prostate cancer patients. There was no
significant difference in BRFS between these two isotopes over the
nine-year follow-up period," said Dr. Moran.
Bill Cavanagh, Chief Scientific
Officer of IsoRay commented, "This is the longest study conducted
to-date for low risk prostate cancer patients treated with
Cesium-131. The durable positive outcomes and statistically
identical results support the consideration of Cesium-131 as a
viable treatment choice for these patients. These results, combined
with the results from the recently published University of Pittsburgh Medical Center study* that
concluded that patients treated with Cesium-131 prostate
brachytherapy are able to recover from prostate cancer treatment
quickly and then maintain their baseline quality of life over the
long term, suggest that brachytherapy with Cesium-131 should be
considered by men with low risk prostate cancer."
* Long-Term Quality of Life in Prostate Cancer Patients Treated
With Cesium-131 Glaser, Scott M. et al., International Journal of
Radiation Oncology • Biology • Physics, Volume 98, Issue 5, 1053 -
1058
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay.
Follow us on Twitter@IsoRay.
Safe Harbor Statement
Statements in this news release about IsoRay, Inc.'s future
expectations, including: the advantages of our products and their
delivery systems, whether the study will ultimately be completed,
whether Cs-131 therapy will demonstrate disease control in large
brain metastasis, and the perception by the patient of quality of
life outcomes or prove to be a safe approach compared to other
treatment options, and all other statements in this release, other
than historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing IsoRay, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released and
support the conclusions of past studies, whether ongoing patient
quality of life results with our products are favorable and in line
with the conclusions of clinical studies and initial patient
results, patient results achieved when our products are used for
the treatment of cancers and malignant diseases in conjunction with
other treatments, successful completion of future research and
development activities, whether we, our distributors, and our
customers will successfully obtain and maintain all required
regulatory approvals and licenses to market, sell, and use our
products in its various forms, continued compliance with ISO
standards as audited by BSI, the success of our sales and marketing
efforts, changes in reimbursement rates, changes in laws and
regulations applicable to our products, and other risks detailed
from time to time in IsoRay, Inc.'s reports filed with the SEC
Securities and Exchange Commission. Unless required to do so by
law, the Company, IsoRay, Inc. undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/isoray-announces-long-term-psa-outcomes-in-a-single-institution-prospective-randomized-cesium-131--iodine-125-permanent-prostate-brachytherapy-trial-poster-presentation-at-2017-annual-american-society-for-radiation-oncology-a-300524910.html
SOURCE IsoRay, Inc.